2007
DOI: 10.1016/s0145-2126(07)70210-2
|View full text |Cite
|
Sign up to set email alerts
|

P140 Factors predicting for a favorable response among patients with myelodysplastic syndromes treated with erythropoietin ± G-CSF

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2011
2011
2015
2015

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…In a recently reported study, a poorer response to ESAs was observed in MDS patients with the following characteristics: transfusion dependence, EPO level Ͼ200 U/L, a morphological diagnosis of refractory anemia with excess blasts (RAEB2) and refractory cytopenia with multilineage dysplasia with ringed sideroblasts (RCMD-RS), and abnormal karyotype [28] (Table 1).…”
Section: Clinical Parametersmentioning
confidence: 96%
“…In a recently reported study, a poorer response to ESAs was observed in MDS patients with the following characteristics: transfusion dependence, EPO level Ͼ200 U/L, a morphological diagnosis of refractory anemia with excess blasts (RAEB2) and refractory cytopenia with multilineage dysplasia with ringed sideroblasts (RCMD-RS), and abnormal karyotype [28] (Table 1).…”
Section: Clinical Parametersmentioning
confidence: 96%
“…In fact, older age was identified as an adverse prognostic factor in a number of different MDS prognostic scoring systems (19)(20)(21). A subsequent study demonstrated that only a limited number of patients with pretreatment serum erythropoietin levels >500 U/l respond to ESA therapy (22).…”
Section: Discussionmentioning
confidence: 99%